Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM) announced on June 18, 2025, that its Board of Directors has approved the appointment of Mr. Diwakar Gupta (DIN: 01274552) as an Additional Director, designated as an Independent Director. The appointment, based on the recommendation of the Nomination and Remuneration Committee and subject to shareholder approval, will be effective from July 13, 2025, for a term of five consecutive years, concluding on July 12, 2030.
| Particulars | Details |
|---|---|
| Name of Appointee | Mr. Diwakar Gupta |
| DIN | 01274552 |
| Designation | Additional Director (designated as Independent Director) |
| Reason for Change | Appointment |
| Date of Appointment (Effective) | July 13, 2025 |
| Term of Appointment | 5 (five) consecutive years, from July 13, 2025, up to July 12, 2030 |
| Approval Process | Recommended by Nomination and Remuneration Committee, approved by the Board of Directors at its meeting on June 18, 2025, subject to the approval of shareholders. |
| Disclosure of relationships between directors | Mr. Diwakar Gupta is not related to any of the Directors of Alkem Laboratories Ltd. |
| Debarment Status | The company confirmed that Mr. Diwakar Gupta is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. |
Detailed Analysis of the Appointment
The Board of Directors of Alkem Laboratories Ltd., in its meeting held on June 18, 2025, formalized the appointment of Mr. Diwakar Gupta. This decision underscores the company's commitment to strengthening its corporate governance framework by inducting experienced professionals onto its board. The appointment is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further details, as required by SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, were provided by the company.
Profile of Mr. Diwakar Gupta
Mr. Diwakar Gupta brings a wealth of experience to the Alkem board, with a distinguished career in banking and financial services spanning over five decades. His expertise is expected to provide valuable insights and strategic guidance to the pharmaceutical major.
Currently, Mr. Gupta holds several prominent positions. He serves as the Non-Executive Chairman of the National Asset Reconstruction Company Limited (NARCL), playing a key role in the resolution of stressed assets in the Indian banking system. He is also a Senior Advisor with True North, a leading India-focused private equity fund, where he contributes his extensive financial acumen.
Mr. Gupta's board-level experience is extensive. He is an Independent Director on the boards of several reputed companies, including:
- CRISIL Ratings Ltd.
- CRISIL ESG Ratings & Analytics Ltd.
- Mahindra Holidays & Resorts India Ltd., and its Finland-based subsidiary, Holiday Club Resorts Oy.
- Mahindra Susten.
- Mahindra & Mahindra Financial Services Ltd.
- SMFG India Credit Company (formerly Fullerton India Credit Company - FICC).
Throughout his career, Mr. Gupta has been closely associated with the Reserve Bank of India (RBI) and various other governmental agencies, contributing to policy-level discussions and initiatives in the financial sector. His deep understanding of the financial landscape, regulatory environment, and corporate governance practices will be a significant asset to Alkem Laboratories.
Significance of the Appointment for Alkem Laboratories
The appointment of an Independent Director of Mr. Gupta's stature is a significant development for Alkem Laboratories. Independent Directors play a crucial role in ensuring transparency, accountability, and ethical conduct within a company. They bring an objective perspective to board deliberations, safeguard the interests of minority shareholders, and contribute to strategic decision-making.
Mr. Gupta's vast experience in finance, risk management, and corporate strategy is particularly relevant for a large, publicly listed company like Alkem. His guidance will be instrumental as the company navigates the dynamic pharmaceutical landscape, explores growth opportunities, and continues to enhance shareholder value. The five-year term provides stability and allows for a long-term contribution to the company's strategic objectives.
Additional Context
About Alkem Laboratories Ltd.
Alkem Laboratories Ltd. (CIN: L00305MH1973PLC174201) is a prominent Indian pharmaceutical company with its registered office at Alkem House, Senapati Bapat Marg, Lower Parel (West), Mumbai. The company operates under the guiding principle of "Inspiring Healthier Lives." It is listed on both the BSE Limited (Scrip Code: 539523) and the National Stock Exchange of India Limited (Scrip Symbol: ALKEM). Alkem has a significant presence in both domestic and international markets, offering a wide range of pharmaceutical formulations and active pharmaceutical ingredients.
Regulatory Compliance and Disclosure
The appointment and its disclosure adhere to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alkem Laboratories has confirmed that Mr. Gupta is not debarred from holding directorships by any regulatory authority, ensuring compliance with corporate governance norms. The company has also stated that Mr. Gupta is not related to any existing directors on the board, further reinforcing the independence of his role.
